Former AZ CMO Bohen brings his cancer chops to Olema

Two months after closing a $54 million series B round, breast cancer company Olema has followed up a flurry of executive hires with the addition of former AstraZeneca CMO Sean Bohen as president and CEO. 

Bohen brings with him a deep track record in developing blockbuster oncology drugs. During his tenure at AstraZeneca plc (LSE:AZN; NYSE:AZN) from August 2015 to April 2019, the pharma had FDA approvals of PD-L1 inhibitor Imfinzi durvalumab, PARP inhibitor Lynparza olaparib, and Tagrisso osimertinib, an oral irreversible inhibitor of EGFR-activating mutations and the T790M EGFR resistance mutation (see “AZ’s Bohen Departing After Cancer-focused Tenure”). ...